Formation of CO2-dependent small-colony variants (SCVs) in methicillin-resistant Staphylococcus aureus mediated by a

Sisi Chen1,2, Wanyang Dong2, Song Li1

  • 1The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Clinical Laboratory/State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510180, China.

Biofilm
|October 16, 2025
PubMed
Abstract

Insights

A single mutation in the mpsB gene causes Staphylococcus aureus to form CO2-dependent small colony variants (CO2-SCVs). These SCVs persist in the host, aiding chronic infections and offering potential therapeutic targets.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Pathogen Research

Background:

  • Staphylococcus aureus is a significant human pathogen.
  • Small colony variants (SCVs) of S. aureus complicate infection treatment.
  • The mechanisms behind CO2-dependent SCVs (CO2-SCVs) are not well understood.

Purpose of the Study:

  • To investigate the genetic basis and characteristics of CO2-SCVs.
  • To identify key genes and pathways involved in CO2-SCV formation.
  • To explore potential therapeutic targets for S. aureus SCV infections.

Main Methods:

  • Whole-genome sequencing of clinical CO2-SCV and normal strains.
  • Transcriptomic profiling to identify differentially expressed genes.
  • Functional validation of identified mutations and pathways.

Main Results:

  • A point mutation (H607Y) in the mpsB gene was linked to the CO2-SCV phenotype.
  • The mpsB mutant showed reduced growth, pigmentation, and increased antibiotic resistance.
  • SCVs exhibited enhanced intracellular persistence and altered cell wall structure.
  • Structural analysis provided mechanistic insights into MpsB function in CO2-SCV formation.

Conclusions:

  • A single mpsB mutation is sufficient to induce the CO2-SCV phenotype.
  • CO2-SCVs play a role in persistent S. aureus infections.
  • The mpsB gene and its associated pathways are potential targets for novel therapeutics.